The Bull Case For Altria (MO) Could Change Following Push Into Non-Tobacco Nicotine Pouches

• Altria Group recently announced a global collaboration with South Korea's KT&G, aiming to co-develop non-tobacco nicotine pouch products and taking an equity stake in Another Snus Factory, the maker of Loop nicotine pouches.
• This move expands Altria's smoke-free portfolio and highlights a shift toward alternatives that could help offset the long-term decline in traditional tobacco sales.
• To assess how this diversification effort shapes Altria's outlook, we'll explore the implications of its push into nicotine pouches on its investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 35 best rare earth metal stocks of the very few that mine this essential strategic resource.

Altria Group Investment Narrative Recap

To be a shareholder in Altria Group, you need to believe in its ability to generate stable cash flows from traditional tobacco while successfully expanding its smoke-free portfolio, particularly amid regulatory and competitive pressures affecting the e-vapor and oral nicotine segments. The recent collaboration with KT&G underscores Altria’s diversification, but its impact on the most immediate catalyst, sustaining high dividend payouts, remains limited for now, while the biggest risk continues to be the regulatory and market headwinds facing both e-vapor and oral products.

Among recent announcements, Altria’s consistent dividend growth stands out, highlighted by its 57th consecutive dividend increase announced in August 2025. This track record of capital returns is especially relevant as investors weigh the company’s push into nicotine pouches and how it may support or offset pressures on its cash distribution capability.

By contrast, investors should be aware that as the company accelerates its shift into modern oral products, heightened regulatory scrutiny and illicit competition may...

Read the full narrative on Altria Group (it's free!)

Altria Group's outlook anticipates $20.3 billion in revenue and $9.1 billion in earnings by 2028. This reflects a -0.1% annual revenue decline and a decrease of $1.1 billion in earnings from the current $10.2 billion.

Uncover how Altria Group's forecasts yield a $62.88 fair value, a 6% downside to its current price.

Exploring Other Perspectives

Simply Wall St Community members place Altria’s fair value between US$48.48 and US$111.64 across nine distinct views, showing strong differences about intrinsic worth. With regulatory challenges clouding key growth areas, you can explore how these contrasting outlooks influence long-term conviction on Altria Group.

Explore 9 other fair value estimates on Altria Group - why the stock might be worth 27% less than the current price!

Build Your Own Altria Group Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Altria Group research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Altria Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Altria Group's overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com